ArticlePharmacoepidemiology and drug safety2025
Antidepressant Use Trajectories and Risk of Discontinuation After Adolescents and Young Adult Cancer Diagnosis.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundLittle is known about the continuity of antidepressant treatment after adolescent and young adult (AYA) cancer diagnosis. Clinical guidelines recommend that past antidepressant use trajectories should inform decisions on discontinuation after cancer diagnosis. We characterized AYAs' antidepressant adherence trajectories before incident cancer diagnosis and assessed any association between their past adherence trajectory and the risk of antidepressant discontinuation up to 1 year afterward.
methodsWe conducted a retrospective, longitudinal cohort study of AYAs receiving ≥ 2 antidepressant fills 9 months before incident cancer diagnosis (index date). Group-based trajectory modeling was used to estimate latent subgroups of antidepressant adherence before cancer diagnosis, using monthly proportions of days covered (PDC) over the nine-month baseline; IQVIA PharMetrics Plus for Academics US claims, 2006-2020. Discontinuation was defined as ≥ 60-days gap without antidepressants within 1 year post-index date.
resultsWe observed three distinct antidepressant adherence trajectory groups before cancer diagnosis: recent start (17% of cohort, mean PDC [range]: 0.25 [0.03-0.49]); gradually increasing (36%, mean PDC [range]: 0.57 [0.22-0.81]); and consistently high (47%, mean PDC [range]: 0.90 [0.62-1.00]). Compared with AYAs exhibiting prior consistently high adherence trajectories, those with recent start (HR, [95% CI] 1.96, [1.46-2.63]) and gradually increasing (HR, [95% CI] 1.52, [1.20-1.93]) trajectories experienced about 2 times the higher risk of antidepressant discontinuation over the year following cancer diagnosis.
conclusionPast antidepressant trajectory is associated with antidepressant discontinuation after AYA cancer diagnosis. Attention is needed in the psycho-oncologic care of AYAs who recently started antidepressants before cancer diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.